: Orchard Therapeutics shares nearly double on buyout deal

Orchard Therapeutics shares ORTX nearly doubled, to $15.79, after agreeing to be purchased by Japan’s Kyowa Kirin JP:4151 for at least $16 per share in cash, plus an additional contingent value right of $1 per share. The total consideration will be as much as $478 million.  London-based Orchard Therapeutics uses a patient’s own stem cells to produce therapies.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.